Reported
January 6, 2003
Is Female Sexual Dysfunction Real?
By Shanida Smith, Ivanhoe Health Correspondent
WASHINGTON (Ivanhoe Newswire) -- A new article in the
British Medical Journal suggests drug companies are behind
the creation of a new medical disorder, female sexual
dysfunction, to build markets for women's drugs.
Journalist Ray Moynihan says estimates indicating 43 percent
of women have female sexual dysfunction are exaggerated and are
being questioned by leading researchers. The controversy
surrounds current attempts to "medicalize" sexual problems, he
says.
Moynihan adds many researchers believe portraying sexual
difficulties as a dysfunction will encourage doctors to
prescribe drugs that change sexual function, when attention
should be paid to other aspects of the woman's life, such as the
emotional and psychological aspects. It is also likely, he says,
to make women think they have a malfunction when they do not.
Moynihan concludes, "The corporate sponsored creation of a
disease is not a new phenomenon, but the making of female sexual
dysfunction is the freshest, clearest example we have." He says
the public needs to scrutinize the role of drug companies when
they promote new conditions.
In an interview with Ivanhoe, Irwin Goldstein, M.D., a
leading urologist from Boston University School of Medicine,
agrees that there needs to be more public scrutiny of drug
companies. However, he says the claim that female sexual
dysfunction is a fabrication is ludicrous.
Dr. Goldstein says, "When sexual issues cause distress, these
men and women have a fundamental right to have their problems
evaluated." He adds the problem is not solely based on emotional
and psychological aspects and needs to be examined from the
medical perspective also, just as other conditions are treated
comprehensively.
Dr. Goldstein says the field of female sexual dysfunction is
"very exciting, new and important, and a poorly understood
field."
This article was reported by Ivanhoe.com, who offers Medical
Alerts by e-mail every day of the week. To subscribe, go to:
http://www.ivanhoe.com/newsalert/.
SOURCE: British Medical Journal, 2003;326:45-47 and
Interview with Irwin Goldstein, M.D., urologist, Boston
University School of Medicine, Jan. 3, 2003